Analysis of aspartate aminotransferase-to-platelet ratio index and liver fibrosis in biliary atresia

Journal of the Colleges of Medicine of South Africa

 
 
Field Value
 
Title Analysis of aspartate aminotransferase-to-platelet ratio index and liver fibrosis in biliary atresia
 
Creator Brits, Elizabeth Brown, Stephen Botes, Lezelle Pienaar, Michael
 
Subject — biliary atresia; liver injury; aspartate aminotransferase-to-platelet ratio index; METAVIR fibrosis score; biomarker; outcome; prognosis
Description Background: The aspartate aminotransferase-to-platelet ratio index (APRi) has been proposed as a non-invasive biomarker of liver injury in biliary atresia (BA). However, conflicting evidence and varying cutoff values have left its association with histologically confirmed liver damage uncertain. This study assessed the relationship between APRi and liver injury severity (Meta-Analysis of Histological Data in Viral Hepatitis [METAVIR] F0–F4) in BA and evaluated its predictive value.Methods: A retrospective analytical review of electronic records was conducted for all BA patients treated at a South African academic hospital between 01 January 2009 and 31 December 2019.Results: Sixty-seven patients were included, 74.6% of whom were female. The most common subtypes were cytomegalovirus (CMV) immunoglobulin M-positive (IgM+) BA (34.3%) and isolated BA (31.3%); about one-third could not be classified because CMV serology was unavailable. Liver biopsy METAVIR scores were F1 (8.3%), F2 (50.0%), F3 (18.3%) and F4 (23.3%). In a sub-analysis (n = 39), APRi modestly differentiated ≤ F2 from ≥ F3 fibrosis at a cutoff of 2.69 (area under the receiver operating characteristic curve 0.61). Decision curve analysis suggested modest clinical utility despite a non-significant logistic regression model (odds ratio 1.25; 95% confidence interval 0.94–1.92; p = 0.2). Of the 55 patients with known outcomes, 94.5% (n = 52) had confirmed mortality or were referred for palliative care.Conclusion: Aminotransferase-to-platelet ratio index should not replace established clinical decision-making but may provide useful adjunctive information alongside clinical, biochemical and histological assessment. These findings provide contextual evidence from a South African resource-limited setting and support prospective multicentre validation before routine clinical implementation.Contribution: The study contributes evidence supporting continued evaluation of APRi as an adjunctive non-invasive biomarker in BA in the South African setting.
 
Publisher AOSIS
 
Contributor —
Date 2026-08-17
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — —
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/jcmsa.v4i1.447
 
Source Journal of the Colleges of Medicine of South Africa; Vol 4, No 1 (2026); 8 pages 2960-110X 3105-4331
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://jcmsa.org.za/index.php/jcmsa/article/view/447/1199 https://jcmsa.org.za/index.php/jcmsa/article/view/447/1200 https://jcmsa.org.za/index.php/jcmsa/article/view/447/1201 https://jcmsa.org.za/index.php/jcmsa/article/view/447/1202
 
Coverage — — —
Rights Copyright (c) 2026 Elizabeth Brits, Stephen Brown, Lezelle Botes, Michael Pienaar https://creativecommons.org/licenses/by/4.0/
ADVERTISEMENT